Methadone maintenance treatment and survival of schizophrenic patients with a lifetime comorbid substance use disorders: a long-term follow-up study

References

• Dole VP, Nyswander ME, Kreek MJ. Narcotic blockade. Arch Intern Med. 1966;118(4):304–9. doi:10.1001/archinte.1966.00290160004002.
   PubMed Web of Science ®Google Scholar
• Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186–216. doi:10.1111/j.1749-6632.2000.tb06683.x.
   PubMed Web of Science ®Google Scholar
• Kreek MJ, Vocci FJ. History and current status of opioid maintenance treatments: blending conference session. J Subst Abuse Treat. 2002;23(2):93–105. doi:10.1016/S0740-5472(02)00259-3.
   PubMed Web of Science ®Google Scholar
• LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2019. Methadone. [Updated 2019 Apr 25]. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK548084/.
   Google Scholar
• Maremmani AGI, Pacini M, Maremmani I. What we have learned from the methadone maintenance treatment of dual disorder heroin use disorder patients. IJERPH. 2019;16(3):447. doi:10.3390/ijerph16030447.
   Google Scholar
• Kreek MJ, Reed B, Butelman ER. Current status of opioid addiction treatment and related preclinical research. Sci Adv. 2019;5(10):eaax9140. doi:10.1126/sciadv.aax9140.
   PubMed Web of Science ®Google Scholar
• Gibson A, Degenhardt L, Mattick RP, Ali R, White J, O'Brien S. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction. 2008;103(3):462–8. doi:10.1111/j.1360-0443.2007.02090.x.
   PubMed Web of Science ®Google Scholar
• Lee CT, Chen VC, Tan HK, Chou SY, Wu KH, Chan CH, Gossop M. Suicide and other-cause mortality among heroin users in Taiwan: a prospective study. Addict Behav. 2013;38(10):2619–23. doi:10.1016/j.addbeh.2013.03.003.
   PubMed Web of Science ®Google Scholar
• Rosca P, Haklai Z, Goldberger N, Zohar P, Margolis A, Ponizovsky AM. Mortality and causes of death among users of methadone maintenance treatment in Israel, 1999-2008. Drug Alcohol Depend. 2012;125(1-2):160–3. doi:10.1016/j.drugalcdep.2012.03.013.
   PubMed Web of Science ®Google Scholar
• Russolillo A, Moniruzzaman A, Somers JM. Methadone maintenance treatment and mortality in people with criminal convictions: A population-based retrospective cohort study from Canada. PLoS Med. 2018;15(7):e1002625. doi:10.1371/journal.pmed.1002625.
   PubMed Web of Science ®Google Scholar
• Cao X, Wu Z, Li L, Pang L, Rou K, Wang C, Luo W, Yin W, Li J, McGoogan JM; National Methadone Maintenance Treatment Program Working Group. Mortality among methadone maintenance clients in China: a six-year cohort study. PLoS One. 2013;8(12):e82476. doi:10.1371/journal.pone.0082476.
   PubMed Web of Science ®Google Scholar
• Evans E, Li L, Min J, Huang D, Urada D, Liu L, Hser Y-I, Nosyk B. Mortality among individuals accessing pharmacological treatment for opioid dependence in California, 2006-10. Addiction. 2015;110(6):996–1005. doi:10.1111/add.12863.
   PubMed Web of Science ®Google Scholar
• Huang CL, Lee CW. Factors associated with mortality among heroin users after seeking treatment with methadone: a population-based cohort study in Taiwan. J Subst Abuse Treat. 2013;44(3):295–300. doi:10.1016/j.jsat.2012.08.003.
   PubMed Web of Science ®Google Scholar
• McCowan C, Kidd B, Fahey T. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ. 2009;338:b2225. doi:10.1136/bmj.b2225.
   PubMedGoogle Scholar
• Rezansoff SN, Moniruzzaman A, Somers JM. Temporal associations between medication adherence for patients with schizophrenia and opioid dependence: A 17-year Canadian Cohort Study. Schizophr Res. 2019;210:157–63. doi:10.1016/j.schres.2019.05.031.
   PubMed Web of Science ®Google Scholar
• Ernst E, Bartu A, Popescu A, Ileutt KF, Hansson R, Plumley N. Methadone-related deaths in Western Australia 1993-99. Aust N Z J Public Health. 2002;26(4):364–70. doi:10.1111/j.1467-842x.2002.tb00188.x.
   PubMed Web of Science ®Google Scholar
• Parpouchi M, Moniruzzaman A, Rezansoff SN, Russolillo A, Somers JM. Characteristics of adherence to methadone maintenance treatment over a 15-year period among homeless adults experiencing mental illness. Addict Behav Rep. 2017;6:106–11. doi:10.1016/j.abrep.2017.09.001.
   PubMedGoogle Scholar
• Gimelfarb Y, Ligay A, Jerusalemsky J, Ben Tzarfati M. The benefit of integrated dual disorders service utilization in the survival of patients in the early stages of schizophrenia and co-occurring substance use disorders: a long-term follow-up study. GJARM. 2017;3(1):555601. doi:10.19080/GJARM.2017.03.555601.
   Google Scholar
• Ministry of Health in Israel, Division of Psychiatry. (December 18, 2017). Administering methadone over 120 mg. Circular number 40.014, 1st edition; 2017.
   Google Scholar
• Peles E, Schreiber S, Domany Y, Adelson M. Impact of lifetime psychiatric diagnosis on long-term retention and survival of former opiate addicts in methadone maintenance treatment. World J Biol Psychiatry. 2014;15(8):629–35. doi:10.3109/15622975.2014.942359.
   PubMed Web of Science ®Google Scholar
• Schiff M, Levit S, Moreno RC. Retention and illicit drug use among methadone patients in Israel: a gender comparison. Addict Behav. 2007;32(10):2108–19. doi:10.1016/j.addbeh.2007.01.010.
   PubMed Web of Science ®Google Scholar
• Sofer MM, Kaptsan A, Anson J. Factors associated with unplanned early discharges from a dual diagnosis inpatient detoxification unit in Israel. J Dual Diagnosis. 2018;14(3):137–47. doi:10.1080/15504263.2018.1461965.
   PubMed Web of Science ®Google Scholar